NASDAQ:MNKD - MannKind Stock Price, Forecast & News

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. The biopharmaceutical company earned $14.60 million during the quarter, compared to the consensus estimate of $15.03 million. During the same quarter last year, the firm posted ($0.16) EPS. View MannKind's Earnings History.

MannKind is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for MannKind.

5 analysts have issued 1-year target prices for MannKind's shares. Their forecasts range from $2.50 to $3.00. On average, they anticipate MannKind's share price to reach $2.90 in the next year. This suggests a possible upside of 139.7% from the stock's current price. View Analyst Price Targets for MannKind.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MannKind.

Media stories about MNKD stock have been trending extremely negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MannKind earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for MannKind.

Some companies that are related to MannKind include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Chesapeake Energy (CHK), Intel (INTC), NVIDIA (NVDA), Alphabet (GOOG) and Micron Technology (MU).

MannKind's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (1.61%), Dupont Capital Management Corp (0.27%), Alps Advisors Inc. (0.20%), 180 Wealth Advisors LLC (0.18%), Creative Planning (0.09%) and Squarepoint Ops LLC (0.06%). Company insiders that own MannKind stock include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross. View Institutional Ownership Trends for MannKind.

MNKD stock was sold by a variety of institutional investors in the last quarter, including Creative Planning and Alps Advisors Inc.. View Insider Buying and Selling for MannKind.

MNKD stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Metropolitan Life Insurance Co NY, Squarepoint Ops LLC, Commonwealth Equity Services LLC, 180 Wealth Advisors LLC, Dupont Capital Management Corp and California Public Employees Retirement System. Company insiders that have bought MannKind stock in the last two years include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross. View Insider Buying and Selling for MannKind.

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MNKD stock can currently be purchased for approximately $1.21.

MannKind has a market capitalization of $249.75 million and generates $27.86 million in revenue each year. The biopharmaceutical company earns $-86,970,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. MannKind employs 225 workers across the globe.View Additional Information About MannKind.

The official website for MannKind is http://www.mannkindcorp.com/.

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]